Coagulation tests
help in measuring the clotting ability of blood. Clotting is the process of
blood converting from liquid into gel form. Coagulation tests are performed to
analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests
include complete blood count, factor V assay, fibrinogen level, prothrombin
time, platelet count, thrombin time, and bleeding time. Coagulation testing
analyzers play a major role in improving patients’ quality of life.
Analysts forecast
the Global Coagulation
Testing market to grow at a
CAGR of 5.62 percent over the period 2013-2018.
The report recognizes
the following companies as the key players in the Global Coagulation Testing
Market: Abbott Laboratories, Danaher Corp., Roche Diagnostics and Sysmex Corp.
Other Prominent
Vendors in the market are: Alere, Cepheid, CoaguSense, Helena Laboratories,
HYPEN BioMed, LABiTec, Medtronic, Siemens, Sienco and Stago.
An expansion of some
of the economies in the APAC region is one of the main trends seen in this
market. Governments in emerging countries are making efforts to improve
healthcare infrastructure, which has benefited the Coagulation Testing market.
Get discount on the
Report @ http://www.sandlerresearch.org/discount?rname=25851
.
Covered in this Report
The Global
Coagulation Testing market can be segmented into the revenue generated from
end- user application such as: Point-of-Care Coagulation Testing and Home
Diagnostics.
Global Coagulation
Testing market 2014-2018, has been prepared based on an in-depth market
analysis with inputs from industry experts. The report covers the Americas, and
the EMEA and APAC regions; it also covers the Global Coagulation Testing market
landscape and its growth prospects in the coming years. The report also
includes a discussion of the key vendors operating in this market.
According to the
report, one of the major drivers in the market is the increase in the
prevalence of cardiovascular disease. CVD deaths occur almost equally in men
and women and it is predicted that by 2030 almost 23.6 million people will die
from CVD. An increase in the prevalence of CVD has led to the development of
coagulation testing products, and thus, the growth of the market.
Further, the report
states that one of the major challenges in the market is the high cost incurred
in R&D activities. Many big vendors are facing the frequent elimination of
coagulation testing analyzer products because of rapid developments with
respect to the technological aspects of coagulation testing analyzers.
Single User License
of the Report is Available at USD 2500, Buy the Report @ http://www.sandlerresearch.org/purchase?rname=25851
.
